Large precision health initiatives like the National Institutes of Health’s All of Us campaign raise important ethical questions about consent, privacy, and inclusivity. This month on Ethics Talk, we explore with Dr Katie Johansen Taber and Ysabel Duron strategies for protecting participants and ensuring that diverse communities are represented.
Trafficking-specific ICD-10-CM codes account for physical, social, and psychological dimensions of trafficked patients’ experiences. Data collected by clinicians can also motivate improvements in health policy, resource allocation, and prevention.
AMA J Ethics. 2018;20(12):E1143-1151. doi:
10.1001/amajethics.2018.1143.
With a focus on health justice, literature review suggests possible relationships between HPV type and geography and demonstrates that insurance status matters.
AMA J Ethics. 2019;21(3):E269-272. doi:
10.1001/amajethics.2019.269.
Where people live and work influences how long and how well they live. Supporting community investments can diminish risk, improve outcomes, and reduce costs.
AMA J Ethics. 2019;21(3):E262-268. doi:
10.1001/amajethics.2019.262.
What are key factors for successful partnerships between health care organizations and communities? We discuss strategies for building trust and engaging effectively.
Rachel Koch, MD, John G. Meara, MD, DMD, MBA, and Anji E. Wall, MD, PhD
Single-procedure interventions with minimal follow-up and clear quality-of-life gain are well suited for surgical mission trips. But not all risks and benefits are easily assessed.
AMA J Ethics. 2019;21(9):E729-734. doi:
10.1001/amajethics.2019.729.
How do we determine what a fair price for a life-saving prescription medication should be? This month, we discuss what is means for a price to be “fair” and explore the current legal and economic landscape of prescription drug pricing in the US.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.